pilot study fluticasone propionate untreated coeliac disease gluten withdrawal likely mainstay treatment adult coeliac disease many patients diet inconvenient unpalatable compliance asymptomatic patients poor Oral corticosteroids patients resistant withdrawal preparations low systemic bioavailability preferable new glucocorticoid fluticasone propionate adults untreated coeliac disease weeks normal diet patient relapse pre-existing neoplasm improvement symptoms mean weight gain kg rise albumin g/l significant improvement lactulose/mannitol excretion ratio histological variables paired biopsy specimens surface crypt intraepithelial lymphocyte/enterocyte goblet cell/enterocyte ratios enterocyte height paired specimens sucrase alkaline phosphatase activity lactase appreciable side effects patients cortisol values synacthen responses weeks normal pretrial results tetracosactrin response weeks propionate worthy assessment treatment coeliac disease adjunct withdrawal 